Company intelligence / Profile preview

EryPharm

Paris, France

Ownership: Private
Development stage: Other

Overview

EryPharm developed and piloted a large-scale platform to manufacture cultured red blood cells (cRBCs) from hematopoietic stem cells as a novel transfusion product designed to reduce transfusion frequency, improve quality of life, and supplement conventional donor blood, but no interventional clinical trial results have been reported publicly to date.[1][2][4][6]

Therapeutic areas: Hematology
Modalities: Cell therapyLive biotherapeutic product therapy
Industry: Biotech

Partnerships

Safi Biotherapeutics (acquirer and strategic integration partner in red blood cell biomanufacturing)[1]

Beyond the preview

Go deeper on EryPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EryPharm.

Explore the full profile